Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arnica Tincture for Cutaneous Leishmaniasis
NCT06822478Phase 3Recruiting
- Sponsor
- Universidad de Antioquia
- Start
- Mar 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of arnica tincture in cutaneous leishmaniasis (CL) (2 arms), sponsored by Universidad de Antioquia. Primary endpoint: Number of participants with healing (scarring) after treatment at 90 days. Started Mar 2026; status: recruiting.
02
Drugs
arnica tincture
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT06822478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06822478.